Open company graph database — free web & API
Login

Astellas Pharma S.A.S

Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
34
§01

Basic information

BASIC
Head office
Tokyo
Chief executive
Naoki Okamura
Capital
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

89
ProductsPipelineRx+ Business CreationPatient PartnershipMedical Intelligence & Patient InsightPatient Insight SolutionsBehavioral Science ConsortiumCulture IntegrationJapanese ProductsCancerOphthalmic DiseasesUrological DiseasesTransplant ImmunologyWomen's HealthHealthXImproving Availability of Astellas ProductsGlobal Health and Social ImpactAstellas Global Health FoundationCharitable ActivitiesSustainability in Business ActivitiesWe provide innovative therapies across diverse areas such as oncology, ophthalmology, urology, immunology, and women's health.Products and disease areasResearch, development, and sale of pharmaceuticalsProvision of digital health solutionsDigital therapeutics for diabetes managementOncologyOphthalmologyUrologyImmunologyWomen's HealthRx+ Business AcceleratorThe standards set forth in the Business Partner Code of Conduct are not intended to change or replacThe basic policy for procurement activitiesRisk assessments for significant business partnerssustainability risk assessmentbusiness partner monitoringon-site audits of supplierssupplier diversityresearch activities to create innovative new drugs and medical solutionsresearch and development activities using stem cellscontributing towards improving the health of people around the world through the provision of innovaBiotechnology and biohazard controlPatent Information Initiative for Medicines (Pat-INFORMED) participationClinical development initiativesclinical trial data disclosureclinical trial registration and results disclosureearly access and post-trial access to investigational therapyAccess to Medicines Request PlatformPosition on Early Access to Investigational TherapyPatient centricity in clinical developmentclinical trialsanti-doping measuresReliable Supply and Quality ManagementEvolution of the Global Manufacturing Networkmanufacturing and supply of medicinesbiologicsgene therapiescell therapiesQuality Management System (QMS)Quality Assurance SystemsQuality AuditsSupply Chain Resilienceproduct supply managementglobal supply chain managementlogistics network managementbusiness continuity planningcrisis managementpatient-centered product designformulation developmentcell therapy technologymedication safety enhancementproduct design for accessibilitypharmaceutical manufacturingbiotechnologycell therapy developmentproduct safety information collection and managementuse of real-world data for product safety evaluationquality standards compliance with cGMPFDA inspection and complianceprovide information on appropriate usage based on on-label information to healthcare professionalsengage with healthcare professionals to exchange scientifically based informationrespond to inquiries regarding productsprovide medical information servicesimplement anti-counterfeiting activitiesanti-counterfeit measuresproduct securitycollaborative activities with pharmaceutical industrysupport and cooperation with regulatory authoritiesrecall system
§04

Related companies

34 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
安川電機株式会社
Alliance
Astellas Pharma Europe Ltd.
Avara Norman Pharmaceutical Services, Inc.
KDDI Corporation
Nippon Medical & Pharmaceutical Co., Ltd.
OSI Pharmaceuticals, Inc
OSI Pharmaceuticals社
OSI Pharmaceuticals Inc.
Takeda Pharmaceutical Company, Limited
Takeda Teba Pharmaceutical Co., Ltd.
Takeda Teba Yakuhin Co., Ltd.
アステラス ファーマ グローバル ディベロップメント Inc.
アステラス ファーマ ヨーロッパ B.V.
アステラス ファーマ ヨーロッパ Ltd.
Astellas Pharma Inc.
AstraZeneca Inc.
アストレージ社
Johnson & Johnson Co., Ltd.
Zepharma Co., Ltd.
Fujisawa Pharmaceutical, Corp.
Fujisawa Healthcare, Inc.
Yusui BV Japan Inc.
Wireless Broadband Planning Co., Ltd.
National Institute of Advanced Industrial Science and Technology
KDD
Yamanochi Pharma America Inc.
山之内薬品商会
Japan Hilti Corporation
Microsoft Japan Inc.
旭化成株式会社
Resonac Holdings Co., Ltd.
Shenyang Shan Zhinui Pharmaceutical Co., Ltd.
DAIICHI SANKYO COMPANY, LIMITED
Fujisawa Pharmaceutical Co., Ltd.
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

43 EVENTS

Fujisawa Pharmaceutical Industry was established in 1894.Sources

Tomoji Fujisawa founded Fujisawa Shoten in Osaka.Sources

Yamanouchi Pharmaceutical was established in 1923.Sources

Fujisawa released camphor as a household insect repellent and deodorizer.Sources

In 1940, the company was renamed Yamanouchi Pharmaceutical Co., Ltd.Sources

Kenji Yamanouchi founded the Yamanouchi Pharmaceutical Association in Osaka.Sources

In 1940, the Yamanouchi Pharmaceutical Association was renamed Yamanouchi Pharmaceutical Co., Ltd.Sources

Kenji Yamanouchi founded the Yamanouchi Pharmaceutical Association in Osaka.Sources

In 1942, the headquarters were moved to Tokyo.Sources

In 1942, the headquarters were relocated to Tokyo.Sources

The company changed its name from Yamanoi Pharmacy Trading Company to Yamanoi Pharmaceutical Co., Ltd.Sources

The company changed its name to Fujisawa Pharmaceutical Industries Co., Ltd.Sources

Fujisawa Pharmaceutical Industries completed its Central Research Laboratory.Sources

Yamanoi Pharmaceutical released the antibiotic josamycin.Sources

Fujisawa Pharmaceutical released the injectable antibiotic cefamidine.Sources

Fujisawa Pharmaceutical established Fujisawa Pharmaceutical, Corp. in the United States.Sources

Fujisawa Pharmaceutical opened its first European base, a London office.Sources

Yamanoi Pharmaceutical released the hypertension treatment drug perdigine.Sources

Fujisawa Pharmaceutical completed its Tsukuba Research Institute.Sources

Yamanoi Pharmaceutical released the H2 receptor antagonist Gaster, now sold in over 100 countries.Sources

Yamanoi Pharmaceutical established Yamanoi Ireland Co., Ltd in Europe, its first overseas active pharmaceutical ingredient production site.Sources

Yamanoi Pharmaceutical completed its Tsukuba Research Institute.Sources

Yamanoi Pharmaceutical acquired the pharmaceutical division of Royal Hist Brokades in the Netherlands.Sources

Fujisawa Pharmaceutical established Fujisawa Europe GmbH in Germany.Sources

Yamanoi Pharmaceutical released the urinary dysfunction improvement drug Harunair, now sold in over 90 countries. Fujisawa Pharmaceutical released the immunosuppressant Prograf, now sold in about 100 countries.Sources

Yamanoi Pharmaceutical established Shenyang Yamanoi Pharmaceutical Co., Ltd. in China.Sources

Fujisawa Pharmaceutical restructured its U.S. operations and established Fujisawa Healthcare, Inc.Sources

Fujisawa Pharmaceutical released the atopic dermatitis treatment drug Protopic, now sold in about 60 countries.Sources

Released the hypercholesterolemia treatment drug Ripitol.Sources

Yamanoi Pharmaceutical established Yamanoi Pharma America Inc. in the United States, creating its own sales base there.Sources

Yamauchi Pharmaceutical released the overactive bladder treatment Vesicare in Europe, and in 2005 also released it in the United States. The two companies integrated their over-the-counter pharmaceutical businesses and established Zepra.Sources

The merger of Yamauchi Pharmaceutical (formerly) and Fujisawa Pharmaceutical Industries (formerly) led to the establishment of Astellas Pharma Inc.Sources

In April 2005, Astellas was founded through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The strengths of Yamanouchi Pharmaceutical in urology and synthetic technology, and Fujisawa Pharmaceutical in transplantation, immunology, and fermentation technology were combined to form an optimal partnership that complements each other.Sources

The leaders of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical shook hands to commemorate the 2005 merger. Through this merger, Astellas was founded, shaping a global strategy centered on patients.Sources

Astellas was established in April 2005 through the merger of two companies – Yamanouchi Pharmaceutical (founded in 1923) and Fujisawa Pharmaceutical (founded in 1894).Sources

Zepra Co., Ltd., which conducted over-the-counter pharmaceutical business, was transferred to Daiichi Sankyo Co., Ltd.Sources

The oral quinolone synthetic antibacterial Geninack™ was launched in Japan, and Agensys, a U.S. biotech venture, was acquired.Sources

Acquired OSI Pharmaceuticals, a U.S. pharmaceutical company.Sources

Betanis™ for overactive bladder was launched in Japan, and the company signed the UN Global Compact.Sources

Wind power was installed at the Kelly plant in Ireland, and a wood biomass boiler began operation. The company joined a new public-private partnership for developing schistosomiasis treatment for preschool children. XTANDI™ for prostate cancer was launched in the United States.Sources

In April 2025, Astellas Pharma celebrated its 20th anniversary.Sources

In April 2025, Astellas Pharma celebrated its 20th anniversary. Astellas was founded in April 2005 through the merger of Yamanouchi Pharmaceutical, established in 1923, and Fujisawa Pharmaceutical, established in 1894. The strengths of Yamanouchi Pharmaceutical in urology and synthetic technology, and Fujisawa Pharmaceutical in transplantation, immunology, and fermentation technology were combined to form an optimal partnership that complements each other.Sources

In April 2025, Astellas celebrated our 20th Anniversary as a company.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑